Eton Pharmaceuticals Inc (ETON)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Eton Pharmaceuticals Inc Stock (ETON) Company Profile

Eton Pharmaceuticals Inc

Healthcare (1113)

(847) 787-7361

21925 W. FIELD PARKWAY, DEER PARK, IL

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ETON's Discussions on Twitter

Compare ETON vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ETON Eton Pharmaceuticals Inc	17.88	467.97M	31.38M	-6.69M	-1.84M	-0.26
TAK Takeda Pharmaceutical Co Adr	18.21	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	126.80	53.16B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.46	47.25B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	32.52	37.59B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	489.64	21.85B	3.13B	1.27B	1.12B	26.39

Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-23	Bestätigt	H.C. Wainwright	Buy
2025-01-10	Eingeleitet	B. Riley Securities	Buy
2025-01-06	Bestätigt	H.C. Wainwright	Buy
2024-09-04	Fortgesetzt	H.C. Wainwright	Buy
2024-05-06	Eingeleitet	Craig Hallum	Buy
2021-10-14	Fortgesetzt	B. Riley Securities	Buy
2021-01-04	Bestätigt	H.C. Wainwright	Buy
2019-09-20	Eingeleitet	B. Riley FBR	Buy
2019-06-10	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Eton Pharmaceuticals Inc Aktie (ETON) Neueste Nachrichten

Finanzdaten der Eton Pharmaceuticals Inc-Aktie (ETON)

Eton Pharmaceuticals Inc (ETON)

Eton Pharmaceuticals Inc Stock (ETON) Company Profile

Compare ETON vs TAK, ZTS, HLN, TEVA, UTHR

Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades

Eton Pharmaceuticals Inc Aktie (ETON) Neueste Nachrichten

HC Wainwright Issues Pessimistic Outlook for ETON Earnings - MarketBeat

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times

Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Date and Conference Call Details - Quiver Quantitative

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, ... - Bluefield Daily Telegraph

Eton inks deal to sell its 10th rare disease drug - Crain's Chicago Business

Craig Hallum Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price - MarketBeat

Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum - TipRanks

Eton Pharmaceuticals acquires U.S. rights to hemangioma drug By Investing.com - Investing.com Canada

Eton Pharmaceuticals Acquires US Commercialization Rights to Pierre Fabre's Hemangeol - marketscreener.com

HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat

Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL - TipRanks

Eton Pharmaceuticals, Inc. announced that, in addition to the acquisition of core assets, the company also plans to purchase approximately $1.5 million worth of inventory products at the time of transaction closing. - Bitget

Understanding Momentum Shifts in (ETON) - Stock Traders Daily

Lumbard & Kellner LLC Buys New Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat

Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire

Only FDA-approved infantile hemangioma drug moves to Eton with $0 co-pays - Stock Titan

Eton Pharmaceuticals (NASDAQ: ETON) licenses U.S. HEMANGEOL rights in orphan drug deal - Stock Titan

Eton Pharmaceuticals' DESMODA Receives FDA Approval - Intellectia AI

US FDA approves Eton Pharma’s hormonal disorder drug - 1470 & 100.3 WMBD

Eton Pharmaceuticals Receives FDA Approval for New Drug Launch - Intellectia AI

Eton Reports US FDA Approval for Desmoda Oral Solution - marketscreener.com

Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy - TipRanks

Eton wins FDA nod for rare disorder therapy Desmoda (ETON) - Seeking Alpha

US FDA approves Eton's liquid therapy for rare water-balance disorder - Reuters

US FDA approves Eton Pharma's hormonal disorder drug - AOL.com

Eton Pharmaceuticals Launches DESMODA™, First FDA-Approved Oral Solution for Central Diabetes Insipidus - Quiver Quantitative

FDA clears first liquid desmopressin for rare water-balance disorder - Stock Titan

US FDA approves Eton’s liquid therapy for rare water-balance disorder - whbl.com

ETON Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

FDA To Decide On ET-600 On February 25: Will It Mark Eton's Ninth Commercial Product? - RTTNews

Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th - The Manila Times

Rare-disease drug maker Eton to meet attendees at Leerink conference - Stock Titan

February 2026's Top Growth Companies With Insider Influence - simplywall.st

Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment - MSN

What are Eton Pharmaceuticals Inc.’s technical support levelsJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru

Volatility Watch: Is Eton Pharmaceuticals Inc a cyclical or defensive stockGap Up & Safe Entry Zone Identification - baoquankhu1.vn

Activity Recap: Is Eton Pharmaceuticals Inc. still a buy after recent gains - mfd.ru

Eton Pharmaceuticals (ETON) Investor Outlook: A Small-Cap Biotech with a 78.68% Potential Upside - DirectorsTalk Interviews

What drives Eton Pharmaceuticals Inc.’s stock priceEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru

We Might See A Profit From Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Soon - simplywall.st

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by Analysts - MarketBeat

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World

Analysts Are Bullish on These Healthcare Stocks: Eton Pharmaceuticals (ETON), HealthStream (HSTM) - The Globe and Mail

Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug By Investing.com - Investing.com South Africa

Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug - Investing.com India

Eton Pharmaceuticals Licenses US Marketing Rights to Ultra-Rare Disease Product - marketscreener.com

Eton Pharmaceuticals licenses ultra-rare disease treatment candidate - Investing.com

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate - The Manila Times

Eton Pharmaceuticals licenses ultra-rare disease treatment candidate By Investing.com - Investing.com UK

Eton Pharmaceuticals Licenses U.S. Marketing Rights for Ultra-Rare Disease Product Candidate, Anticipates FDA Approval by Mid-2026 - Quiver Quantitative

Aug Drivers: What drives Eton Pharmaceuticals Incs stock priceJuly 2025 Macro Moves & Real-Time Volume Analysis - baoquankhu1.vn

Finanzdaten der Eton Pharmaceuticals Inc-Aktie (ETON)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ETON